PI3Kδ inhibition alters CD8 T cell differentiation and reprograms the tumor microenvironment following adoptive immunotherapy
The Journal of Immunology · 2026
DOI: 10.1093/jimmun/vkag108 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Immunology, 2026. Verfasst von Alexandrea Turnquist und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth College, Lebanon, NH, United States. Hauptthemen laut MEDLINE: Tumor Microenvironment, Immunotherapy, Adoptive, CD8-Positive T-Lymphocytes, Melanoma, Experimental. Die Arbeit nennt 79 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIGMS NIH HHS, NIH HHS.
Abstract (Originalsprache)
T cell exhaustion remains a significant barrier to effective adoptive cell therapy in solid tumors. Here, we demonstrate that in vitro treatment with the PI3Kδ inhibitor CAL-101 generates T cells with enhanced stemness and metabolic fitness. These cells show increased mitochondrial dependence and spare respiratory capacity while maintaining normal basal metabolism. Under chronic antigen stimulation, CAL-101–treated T cells, including human T cells, resist terminal exhaustion and maintain stem-like properties. Using single-cell RNA sequencing and spatial transcriptomics of B16 melanoma tumors, we found that CAL-101–treated T cells preferentially differentiate into progenitor exhausted T cells within the tumor microenvironment. These cells demonstrate enhanced tumor infiltration and upregulate the Cxcl10/Cxcr3 signaling axis. The tumor microenvironment of tumors containing CAL-101–treated T cells show reduced glycolysis, oxidative phosphorylation, and proliferation, while exhibiting increased proinflammatory signaling and decreased presence of immunosuppressive tumor-associated macrophages. Single-cell analysis reveals that the CAL-10–treated T cells concurrently increase oxidative phosphorylation, proliferation, and immune signaling pathways. Mechanistically, CAL-101–treated T cells maintain high expression of stemness-associated genes (Tcf7, Slamf6) while resisting expression of genes associated with terminal exhaustion (Tim3, Mt1/2). These findings reveal the mechanisms behind how PI3Kδ inhibition generates T cells capable of establishing and maintaining an antitumor immune response, suggesting a promising strategy for improving adoptive cell therapy outcomes in solid tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth College, Lebanon, NH, United States.
- Department of Biomedical Data Science, Geisel School of Medicine at Dartmouth College, Lebanon, NH, United States.
- Dartmouth Single Cell Genomics Core, Geisel School of Medicine at Dartmouth College, Lebanon, NH, United States.
- Department of Surgery, Emory University School of Medicine, Atlanta, GA, United States.
Förderung
- NIAID NIH HHS
- NIGMS NIH HHS
- NIH HHS
- NCI NIH HHS
- National Institutes of Health
Zitieren
APA
Turnquist, A., Javaid, A., Wilkins, O. M., Kolling Iv, F., Pioli, P. A., Paulos, C. M., Robert Frost, H., & Usherwood, E. J. (2026). PI3Kδ inhibition alters CD8 T cell differentiation and reprograms the tumor microenvironment following adoptive immunotherapy. The Journal of Immunology. https://doi.org/10.1093/jimmun/vkag108
Vancouver
Turnquist A, Javaid A, Wilkins OM, Kolling Iv F, Pioli PA, Paulos CM, et al. PI3Kδ inhibition alters CD8 T cell differentiation and reprograms the tumor microenvironment following adoptive immunotherapy. The Journal of Immunology. 2026. doi:10.1093/jimmun/vkag108
BibTeX
@article{Turnquist2026,
author = {Turnquist, Alexandrea and Javaid, Azka and Wilkins, Owen M and Kolling Iv, Fred and Pioli, Patricia A and Paulos, Chrystal M and Robert Frost, Hildreth and Usherwood, Edward J},
title = {PI3Kδ inhibition alters CD8 T cell differentiation and reprograms the tumor microenvironment following adoptive immunotherapy},
journal = {The Journal of Immunology},
year = {2026},
doi = {10.1093/jimmun/vkag108}
}
EUVIMED